Activating mutations in the BRAF gene have also been identified in non-melanoma tumors, including thyroid, colorectal carcinomas, lung cancer, and hairy cell leukemia [109], and were linked to the glycolytic phenotype in both in vitro and in vivo cancer models [110, 111]. The gene discussed is BRAF; the disease is melanoma.